NEWARK, Calif., May 4, 2020 /PRNewswire/ -- Protagonist
Therapeutics, Inc. (Nasdaq:PTGX) will announce first quarter
financial results after the NASDAQ market closes on Thursday, May 7, 2020. Protagonist management
will host a conference call to provide a corporate and R&D
update at 5:00 p.m. EDT/2:00 p.m. PDT the same day.
Conference Call and Webcast Information
Protagonist executives will host a conference call at
5:00 p.m. EDT/2:00 p.m. PDT on Thursday, May 7, 2020. To access
the live call, dial 1-844-515-9178 (U.S./Canada) or 1-614-999-9313 (international) and
refer to conference ID number 4597494. A live and archived webcast
of the call will also be accessible in the Investors section of the
Company's website at www.protagonist-inc.com. A replay will be
available on the company's website approximately two hours after
the call and will remain available for 60 days.
About Protagonist Therapeutics, Inc.
Protagonist Therapeutics is a clinical stage biopharmaceutical
company that utilizes a proprietary technology platform to discover
and develop novel peptide-based drugs to address significant unmet
medical needs and transform existing treatment paradigms for
patients. The Company currently has three different assets in
various stages of clinical development. All three were discovered
through the use of the Company's peptide technology platform.
PTG-300 is an injectable hepcidin mimetic in development for the
potential treatment of iron overload and related blood disorders,
including hereditary hemochromatosis and rare diseases such as
beta-thalassemia and polycythemia vera. PTG-200 is an orally
delivered, gut-restricted interleukin-23 receptor specific
antagonist peptide in Phase 2 clinical development for the
potential treatment of inflammatory bowel disease, with Crohn's
disease as the initial indication. The Company has a worldwide
license and collaboration agreement with Janssen Biotech, Inc., for
the clinical development of PTG-200. PN-943 is an orally delivered,
gut-restricted alpha-4-beta-7 integrin specific antagonist peptide
in clinical development for the potential treatment of inflammatory
bowel disease and a Phase 2 study with PN-943 in ulcerative colitis
study is planned.
Protagonist is headquartered in Newark, California. For further information,
please visit http://www.protagonist-inc.com.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/protagonist-therapeutics-to-announce-first-quarter-2020-financial-results-and-provide-corporate-and-rd-update-301051233.html
SOURCE Protagonist Therapeutics, Inc.